@article{oai:shiga-med.repo.nii.ac.jp:00003942,
 author = {窪田, 成寿 and 影山, 進 and 永澤, 誠之 and 和田, 晃典 and 伊狩, 亮 and 富田, 圭司 and 吉田, 哲也 and 成田, 充弘 and 河内, 明宏 and KUBOTA, Shigehisa and KAGEYAMA, Susumu and NAGASAWA, Masayuki and WADA, Akinori and IKARI, Ryo and TOMITA, Keiji and YOSHIDA, Tetsuya and NARITA, Mitsuhiro and KAWAUCHI, Akihiro},
 journal = {The American journal of case reports},
 month = {Jul},
 note = {pdf, BACKGROUND:
Cabazitaxel is a second-generation taxane approved for patients with metastatic castration-resistant prostate cancer (CRPC). Although cabazitaxel improves overall survival when used following docetaxel chemotherapy, duration of the clinical response is relatively short, and few patients achieve a long-term response., CASE REPORT:
A 71-year-old man with prostate adenocarcinoma with an initial prostate-specific antigen (PSA) level of 4956 ng/ml, Gleason score 4+5 and cTxN0M1b was referred to our department for treatment. Several therapeutic approaches, including androgen deprivation therapy, with a combination of bicalutamide and a luteinizing hormone-releasing hormone analogue, and 4 sequential hormonal therapies including flutamide, estramustine, enzalutamide, and abiraterone, all failed to prevent disease progression. Subsequently, after 5 cycles of docetaxel chemotherapy were also ineffective, cabazitaxel chemotherapy at a dose of 20 mg/m² together with prednisone and pegfilgrastim was initiated. The patient developed grade 4 thrombocytopenia during the first 4 cycles, and the dosage of cabazitaxel had to be tapered to 12.5 mg/m² by the fifth cycle. In subsequent cycles, the treatment was continued without grade 4 thrombocytopenia or any other toxicities ³grade 3. The patient achieved a long-term clinical response over 4 years and his PSA level continued to decrease, from 29.8 ng/ml at treatment initiation to a nadir of 2.0 ng/ml after the 60th cycle., CONCLUSIONS:
The present case is a rare example of a sustained response to low-dose cabazitaxel, and suggests its potential as a treatment option for metastatic CRPC patients. In our patient, this approach achieved a good clinical response with manageable toxicity over the long term., Journal Article},
 title = {Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer : A Case Report.},
 volume = {22},
 year = {2021}
}